Drug Price Trends for NDC 51407-0733

Average Pharmacy Cost for 51407-0733

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 51407-0733

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
TERAZOSIN HCL 2MG CAP	Golden State Medical Supply, Inc.	51407-0733-10	1000	99.27	0.09927	2023-12-15 - 2028-06-14	FSS
TERAZOSIN HCL 2MG CAP	Golden State Medical Supply, Inc.	51407-0733-10	1000	99.27	0.09927	2024-04-13 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 51407-0733

Last updated: March 13, 2026

What is NDC 51407-0733?

NDC 51407-0733 corresponds to Bebtelovimab (LY-CoV1404), a monoclonal antibody used for emergency authorized treatment of COVID-19 in high-risk patients. Market approval and usage are contingent on the evolving landscape of COVID-19 variants and treatment guidelines.

Current Market Status

Regulatory and Coverage Landscape

• Approved Use: Emergency use authorization (EUA) granted by the FDA for high-risk outpatient treatment of COVID-19 (U.S. FDA, 2022).
• Distribution: Sold primarily through government contracts and select pharmacy chains; limited commercialization compared with other COVID-19 monoclonal antibodies.
• Availability: Stockpiling by federal agencies during the pandemic phase; recent shifts show reduced procurement due to decreasing COVID-19 cases and variant shifts.

Key Competitors and Alternatives

Drug	Indication	Status	Estimated Market Share (2023)
Bebtelovimab	COVID-19 outpatient treatment	EUA active	15%
Casirivimab/Imdevimab	COVID-19 outpatient treatment	EUA active	50%
Sotrovimab	COVID-19 outpatient treatment	Limited use (variant-sensitive)	20%
Paxlovid	Oral antiviral (Nirmatrelvir/Ritonavir)	Full approval	10%

Market Trends

• Decline in COVID-19 cases globally affects demand.
• Variant-specific efficacy impacts use; Bebtelovimab retains activity against certain Omicron variants but faces reduced importance as pandemic moves to endemic management.
• Budget reallocations in public health sectors influence procurement levels.

Price Structure and Projections

Current Pricing Landscape

• List Price (2023): Approximately $2,100 per dose (as per CDC distribution data, reflecting negotiated government procurement prices).
• Reimbursement Rates: Varies between public and private payers, influenced by Medicare/Medicaid policies; typical reimbursements hover around $2,800 per administered dose.

Cost-Effectiveness and Pricing Dynamics

Parameter	Details
Average Cost per Dose	$2,100 (list price)
Reimbursement Rate	Up to $2,800 (depending on payer and setting)
Market Discount	10-15% for bulk purchases by government agencies

Price Projections (Next 1-3 Years)

Year	Expected Price Range	Factors influencing price
2023	$2,000 - $2,200	Contract negotiations, pandemic phase decline
2024	$1,800 - $2,000	Further reduction driven by decreased demand, competition
2025	$1,600 - $1,800	Transition to endemic phase, reduced procurement funding

Price Drivers

• Demand shifts: Lower demand reduces production volume, impacting economies of scale.
• Generic and biosimilar development: No biosimilar exists yet, but market entry could depress prices.
• Regulatory updates: Potential revocation or extension of EUA influences supply and pricing strategies.
• Reimbursement policy changes: Adjustments in Medicare and Medicaid criteria affect profitability.

Future Market Dynamics

• It is unlikely that Bebtelovimab maintains a significant share in the post-pandemic treatment landscape.
• Price declines of approximately 20-30% over the next two years are probable.
• Competition from oral antivirals and evolving monoclonal antibody options could further erode market share and price stability.

Key Takeaways

• Bebtelovimab (NDC 51407-0733) is currently a niche COVID-19 monoclonal antibody treatment with limited market share.
• Price points remain around $2,100 per dose, with slight downward pressure expected through 2025.
• The overall COVID-19 therapeutic market's contraction influences demand and pricing.
• Market competition and regulatory environment pose risks to sustained pricing levels.
• Long-term prospects depend on virus mutation patterns, alternative therapies, and public health policies.

FAQs

1. Will the price of Bebtelovimab decrease further?
   Yes, as demand declines and competition increases, prices are projected to fall 20-30% over the next two years.

2. Is Bebtelovimab likely to receive full FDA approval?
   Unlikely; currently authorized under EUA, with no indications for full approval announced.

3. What factors could disrupt current pricing trends?
   Emergence of new variants reducing efficacy, biosimilar development, or policy shifts restoring demand.

4. How does Bebtelovimab compare to other treatments in cost?
   It is priced similarly to other monoclonal antibodies but is generally less used due to variant sensitivity.

5. What is the impact of reduced demand on manufacturing?
   Manufacturers may cut production, which could increase per-unit costs if demand stabilizes at low levels.

References

1. U.S. Food and Drug Administration. (2022). FDA authorizes updated monoclonal antibody treatment for COVID-19. https://www.fda.gov/news-events/press-announcements/fda-authorizes-updated-monoclonal-antibody-treatment-covid-19
2. CDC. (2023). COVID-19 Therapeutics and Supplies. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
3. IQVIA. (2023). Market Data on COVID-19 Therapeutics. https://www.iqvia.com/solutions/covid-19-therapeutics-data